Needham Maintains Buy on ShockWave Medical, Raises Price Target to $330
Portfolio Pulse from richadhand@benzinga.com
Needham analyst Mike Matson maintains a 'Buy' rating on ShockWave Medical (NASDAQ:SWAV) and raises the price target from $325 to $330.
August 08, 2023 | 10:33 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Mike Matson maintains a 'Buy' rating on ShockWave Medical and raises the price target from $325 to $330.
The raised price target by Needham analyst indicates a positive outlook for ShockWave Medical. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100